Compare HP & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HP | HCM |
|---|---|---|
| Founded | 1920 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | N/A | N/A |
| Metric | HP | HCM |
|---|---|---|
| Price | $32.40 | $16.04 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 11 | 1 |
| Target Price | ★ $30.27 | $13.75 |
| AVG Volume (30 Days) | ★ 1.4M | 55.1K |
| Earning Date | 02-04-2026 | 08-07-2025 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | ★ $3,746,013,000.00 | $602,197,000.00 |
| Revenue This Year | $9.18 | N/A |
| Revenue Next Year | $3.91 | $15.54 |
| P/E Ratio | ★ N/A | $5.57 |
| Revenue Growth | ★ 35.89 | N/A |
| 52 Week Low | $14.65 | $11.51 |
| 52 Week High | $37.30 | $19.50 |
| Indicator | HP | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 67.60 | 75.72 |
| Support Level | $31.40 | $14.63 |
| Resistance Level | $32.97 | $15.00 |
| Average True Range (ATR) | 1.20 | 0.42 |
| MACD | 0.22 | 0.26 |
| Stochastic Oscillator | 89.87 | 90.63 |
Helmerich & Payne Inc provides performance-driven drilling solutions and technologies to make hydrocarbon recovery safer and more economical for oil and gas exploration and production companies. Focusing on the drilling segment, its technology services develop and commercialize solutions that improve drilling efficiency, accuracy, and wellbore quality and placement. The company operates through North America Solutions, International Solutions, and Offshore Solutions segments. The North America segment runs a technologically advanced AC drive drilling rig fleet in the U.S., with a presence in shale and unconventional basins, while the Offshore Solutions segment, operating rigs on fixed-leg and floating platforms, generates the majority of revenue.
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.